Bacil Pharma Intrinsic Value
Bacil Pharma (BACPHAR) median intrinsic value is ₹21.12 from 5 valuation models (range ₹12–₹36), vs current price ₹39.85 — -47.0% downside (Trading Above Calculated Value), margin of safety -88.7%. Read BACPHAR dividend yield for the complete payout history and dividend yield track record.
BACPHAR Valuation Methods Summary — DCF, Graham Number & P/E
Bacil Pharma intrinsic value across 5 models vs current price ₹39.85 — upside/downside and value range per method. Analyse BACPHAR shareholding pattern to track promoter, FII and institutional holdings.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹24.42 | ₹19.54 - ₹29.30 | -38.7% | EPS: ₹1.11, Sector P/E: 22x |
| Book Value Method | asset | ₹35.71 | ₹32.14 - ₹39.28 | -10.4% | Book Value/Share: ₹17.86, P/B: 2.0x |
| PEG Ratio Method | growth | ₹11.96 | ₹10.76 - ₹13.16 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹17.15 | ₹15.43 - ₹18.86 | -57.0% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| Graham Defensive Method | conservative | ₹21.12 | ₹19.01 - ₹23.23 | -47.0% | EPS: ₹1.11, BVPS: ₹17.86 |
BACPHAR Intrinsic Value vs Market Price — All Valuation Models
Bacil Pharma fair value range ₹12–₹36 vs current market price ₹39.85 across 5 valuation models. For current market price and key ratios, visit Bacil Pharma share price chart.
BACPHAR Intrinsic Value Analysis — Undervalued or Overvalued?
Bacil Pharma median intrinsic value ₹21.12, current price ₹39.85 — Trading Above Calculated Value by 47.0%, margin of safety -88.7%.
What is the intrinsic value of BACPHAR?
Based on our comprehensive analysis using 5 different valuation methods, the estimated intrinsic value of Bacil Pharma (BACPHAR) is ₹21.12 (median value). With the current market price of ₹39.85, this represents a -47.0% variance from our estimated fair value.
The valuation range spans from ₹11.96 to ₹35.71, indicating ₹11.96 - ₹35.71.
Is BACPHAR undervalued or overvalued?
Based on our multi-method analysis, Bacil Pharma (BACPHAR) appears to be trading above calculated value by approximately 47.0%.
BACPHAR Financial Health — Key Ratios vs Industry Benchmarks
Bacil Pharma financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Return on Equity | 4.0% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
BACPHAR Cash Flow Quality — Operating & Free Cash Flow
Bacil Pharma operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹-4 Cr | ₹-4 Cr | Negative Cash Flow | 3/10 |
| March 2021 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |